A detailed history of Simplex Trading, LLC transactions in Kezar Life Sciences, Inc. stock. As of the latest transaction made, Simplex Trading, LLC holds 3,788 shares of KZR stock, worth $2,045. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,788
Previous 933 306.0%
Holding current value
$2,045
Previous $0 Infinity%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 25, 2024

BUY
$0.6 - $0.92 $1,713 - $2,626
2,855 Added 306.0%
3,788 $2,000
Q1 2024

Apr 25, 2024

SELL
$0.8 - $1.05 $1,997 - $2,621
-2,497 Reduced 72.8%
933 $0
Q4 2023

Feb 02, 2024

SELL
$0.72 - $1.15 $7,590 - $12,124
-10,543 Reduced 75.45%
3,430 $3,000
Q3 2023

Nov 01, 2023

BUY
$1.08 - $2.54 $11,566 - $27,203
10,710 Added 328.23%
13,973 $16,000
Q2 2023

Aug 04, 2023

SELL
$2.31 - $3.06 $9,681 - $12,824
-4,191 Reduced 56.22%
3,263 $7,000
Q1 2023

Apr 27, 2023

BUY
$3.13 - $7.31 $23,331 - $54,488
7,454 New
7,454 $23,000
Q3 2022

Nov 04, 2022

SELL
$7.99 - $10.75 $132,546 - $178,331
-16,589 Reduced 63.1%
9,700 $83,000
Q2 2022

Aug 03, 2022

BUY
$4.58 - $17.13 $96,940 - $362,573
21,166 Added 413.16%
26,289 $217,000
Q1 2022

May 02, 2022

SELL
$12.3 - $18.33 $127,723 - $190,338
-10,384 Reduced 66.96%
5,123 $85,000
Q4 2021

Feb 23, 2022

BUY
$7.44 - $16.72 $115,372 - $259,277
15,507 New
15,507 $259,000
Q2 2021

Aug 12, 2021

SELL
$4.93 - $6.46 $2,026 - $2,655
-411 Closed
0 $0
Q1 2021

Apr 26, 2021

SELL
$5.24 - $6.99 $1,938 - $2,586
-370 Reduced 47.38%
411 $2,000
Q4 2020

Feb 02, 2021

BUY
$4.77 - $6.58 $1,507 - $2,079
316 Added 67.96%
781 $4,000
Q3 2020

Oct 14, 2020

SELL
$4.36 - $5.5 $2,044 - $2,579
-469 Reduced 50.21%
465 $2,000
Q2 2020

Jul 13, 2020

BUY
$3.6 - $7.75 $3,362 - $7,238
934 New
934 $4,000

Others Institutions Holding KZR

About Kezar Life Sciences, Inc.


  • Ticker KZR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,369,504
  • Market Cap $36.9M
  • Description
  • Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...
More about KZR
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.